📰 8 sources covering this story

AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant

First covered 12 hrs ago · latest take 1 hrs ago. Compare how each outlet is covering it — and rate the sources you trust.

AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant
AstraZeneca abandons lung cancer treatment trial in fresh setback for drugs giant
The trial being halted comes as another blow to the pharmaceutical company
STAT News
STAT News5 hrs ago
STAT+: Akeso and Summit’s lung cancer drug shows worsening tumor-progression benefit
Europe pulls Tavneos over trial integrity concerns, pricing concerns over AstraZeneca's hypertension drug, and more biotech news from The Readout
AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review - WSJ
AstraZeneca Ends Phase 3 Lung Cancer Drug Trial After Review  WSJ
The Times
The Times10 hrs ago
AstraZeneca posts two wins and a setback for lung cancer pipeline
AstraZeneca posts two wins and a setback for lung cancer pipeline  The Times
AstraZeneca ditches lung cancer treatment trial
The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.
Irish News
Irish News11 hrs ago
AstraZeneca ditches lung cancer treatment trial
The FTSE 100 firm stopped a stage volrustomig drug trial a month after halting a trial for a new heart disease treatment.
Reuters
Reuters🏁 first to report12 hrs ago
AstraZeneca to discontinue late-stage lung cancer trial for volrustomig
AstraZeneca to discontinue late-stage lung cancer trial for volrustomig  Reuters
Top rated outlets
Outlets are ranked once they have 3+ community ratings — be one of the first to rate.
🏆 Most trusted sources 2026 →
Scores come entirely from reader ratings — rate the sources you read to shape them. How it works →